摘要:
The present invention provides novel methods for synthesizing PPARy sparing compounds, e.g., thiazolidinediones, that are useful for preventing and/or treating metabolic disorders such as diabetes, obesity, hypertension, and inflammatory diseases.
摘要:
Disclosed is a novel compound having an effect of inhibiting the production/secretion of ß-amyloid protein. A compound represented by the general formula (1) or a salt or a solvate of the compound or the salt; and a pharmaceutical agent comprising the compound, salt or solvate.
摘要:
The present invention relates to a process for preparing tetrasubstituted imidazole derivatives of the general formula (I) wherein R , R , R and R are as defined in the specification below.The present invention further relates to a process for preparing the compound of formula (II) and novel crystalline structures of the compound of formula (II).
摘要:
The present invention relates to an efficient process for preparing derivatives of 1-(pyridinyl)-1, 1-dialkoxy-2-aminoethane of the formula (I), with which compounds of the formula (I) can be prepared in high purity and yield and in the form of the free base without isolating the acetylpyridine oxime of the formula (XI) which is a critical product from a safety point of view as a solid.
摘要:
The present invention relates to an efficient process for preparing derivatives of 1-(pyridinyl)-1, 1-dialkoxy-2-aminoethane of the formula (I), with which compounds of the formula (I) can be prepared in high purity and yield and in the form of the free base without isolating the acetylpyridine oxime of the formula (XI) which is a critical product from a safety point of view as a solid.
摘要:
The present invention relates to an efficient process for preparing derivatives of 1-(pyridinyl)-1, 1-dialkoxy-2-aminoethane of the formula (I), with which compounds of the formula (I) can be prepared in high purity and yield and in the form of the free base without isolating the acetylpyridine oxime of the formula (XI) which is a critical product from a safety point of view as a solid.
摘要:
The invention relates to processes and intermediates for manufacturing fused heterocyclic-type kinase inhibitor compounds, such as thienopyridine-based compounds, and to processes and intermediates for preparing intermediates that are useful in the manufacture of fused heterocyclic-type kinase inhibitor compounds, particularly at an industrial level The processes are aimed at ultimately forming compounds of the formula (A) where M is thieno[3,2,b]pyridinyl as shown, the group D is a ring or ring system, preferably pyridine, and the group Z, Ar, and G are as defined herein Such compounds can act to inhibit the protein tyrosine kinase activity of growth factor receptors, resulting in the inhibition of receptor signalling, for example, the inhibition of VEGF receptor signalling and HGF receptor signalling.
摘要:
A method is described for the preparation of aryl-pyridine compounds of formula (I) by cross-coupling reaction, promoted by catalytic systems based on palladium or nickel between compounds of formula (II) and (III) in which: - Met represents Mg or Zn, - Y represents C1, Br, I or acetoxy, - Z represents I, Br, Cl, triflate, sulphonate, phosphate, - R l , R 2 , R 3 , R 4 , which are the same as one another or different, represent hydrogen, a linear and/or branched C l -C 4 alkyl, and/or an aryl, and/or a heteroaryl, or R l and R 2 and/or R 3 and R 4 , taken together, form a C 3 -C 8 ring, an aryl and/or a heteroaryl, - A represents -COR 5 where R 5 represents hydrogen, a linear and/or branched C l -C 4 alkyl, and/or an aryl, and/or a heteroaryl, or - A represents -CR s5 (OR 6 )(OR 7 ) where R 5 has the meaning described above and R 6 and R 7 , which are the same as one another or different, represent a linear and/or branched C 1 -C 4 alkyl, and/or an aryl, and/or a heteroaryl, or R 6 and R 7 , joined together, represent a C 1 -C 8 alkyl or alkenyl.
摘要:
The present invention relates to a process for preparing tetrasubstituted imidazole derivatives of the general formula (I) wherein R 1 , R 2 , R 3 and R 4 are as defined in the specification below.The present invention further relates to a process for preparing the compound of formula (II) and novel crystalline structures of the compound of formula (II).